Clinical Trial Update: Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial is evaluating the addition of tazemetostat to pembrolizumab in locally advanced or metastatic urothelial carcinoma of the bladder. Th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma of the Bladder

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• Tazemetostat (tazemetostat)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING